PARIS , Oct. 21, 2024 /PRNewswire/ -- Okomera announces Bpifrance funding to develop and standardize novel CRISPR screening assay to accelerate drug discovery in oncology with leading cancer research center of Marseille , CRCM. Okomera is developing desktop platform for automated organoid screening using droplet-microfluidics and AI to accelerate drug discovery.
Their patented tech developed after 10 years of research at Pasteur Institute and Ecole Polytechnique, provides Multiplexing, Co-culture and High-throughput screening of drug candidates on miniaturized Patient Derived Organoids (PDOs). "We are honored to receive this grant from Bpifrance," said Sidarth Radjou, CEO of Okomera. Dr.
Thomas Miller , Principal Investigator at IPC and CRCM, emphasized the significance of this collaboration: "This partnership is an extraordinary opportunity to advance our understanding of cancer biology. By developing and standardizing a CRISPR screening assay that can be directly applied to PDOs, we can create more accurate disease models. This will not only improve our ability to study cancer mechanisms but also enhance our capability to identify new therapeutic targets and develop more effective treatments.
" "We are thrilled to embark on this collaboration, as it offers an unprecedented opportunity to leverage cutting-edge technologies in cancer research," said Dr. Geraldine Guasch , Research Director Inserm at CRCM and Scientific Director of the 3D-HUB-O organoid platform. "By integratin.